MedPath

To assess frequency of Diffuse Large B Cell Lymphoma genetic subtypes in India

Not Applicable
Conditions
Health Condition 1: null- Denovo DLBCL cases registered at Tata Memorial Center from 2007 to 2013 will be screened. Out of these 350 cases will be enrolled based on availability of FFPEHealth Condition 2: D728- Other specified disorders of whiteblood cells
Registration Number
CTRI/2018/10/016107
Lead Sponsor
Duke Cancer Institute for Genome Science and Policy
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1 Age >15 years

2 Denovo DLBCL cases who were treated in department of Medical Oncology

Exclusion Criteria

1.Non availability of formalin- fixed paraffin blocks

2.Non availability of Outcome Data

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Evaluating the frequency of GCB and ABC DLBCL subtypes with gene expression <br/ ><br>2. Comparison of frequency of DLBCL molecular subtypes (comparison of our data set with that of North America- Dr Daveâ??s lab data) <br/ ><br>3. RNA sequencing to identify DLBCL subtypes and its correlation with GEP subtypes profiling <br/ ><br>Timepoint: 3 years
Secondary Outcome Measures
NameTimeMethod
Effect of ABC and GCB subtypes on overall survivalTimepoint: 36 months
© Copyright 2025. All Rights Reserved by MedPath